Lisata Therapeutics, Inc.

NasdaqCM:LSTA 株式レポート

時価総額：US$28.4m

Lisata Therapeutics 配当と自社株買い

配当金 基準チェック /06

Lisata Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-2.8%

バイバック利回り

総株主利回り-2.8%
将来の配当利回りn/a
配当成長n/a
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

ナラティブの更新 • May 02

LSTA: Higher Growth Outlook Will Offset Going Concern Liquidity Risk

Analysts have reset their 12 month price target for Lisata Therapeutics from $11.33 to $9.50, reflecting updated assumptions for revenue growth, profit margin, and a lower forward P/E multiple in their models. What's in the News Lisata Therapeutics filed its 10 K on March 12, 2026 for the period ending December 31, 2025, providing updated audited financial statements and disclosures for the year.
ナラティブの更新 • Apr 17

LSTA: Kuva Cash Deal Will Support Future Upside Potential

Analysts have adjusted their price target on Lisata Therapeutics to $15.00 from $15.00, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E while referencing the recent downgrade highlighted in Street research. Analyst Commentary Bullish analysts looking at Lisata Therapeutics are framing the updated US$15.00 price target within a wider debate about how quickly the company can execute on its pipeline and how much of that potential is already reflected in the shares.
ナラティブの更新 • Apr 03

LSTA: Kuva Cash Deal And Pipeline Milestones Will Support Future Upside Potential

Analysts have reduced their price target on Lisata Therapeutics to $15.00, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E following recent research that included a downgrade at Brookline. Analyst Commentary Recent research points to a more cautious stance on Lisata Therapeutics, yet there are still several areas that bullish analysts highlight as potential positives for long term holders.
ナラティブの更新 • Mar 20

LSTA: Brookline Downgrade And Kuva Cash Deal Will Reset Upside Expectations

Analysts have revised their price target for Lisata Therapeutics to $15.00, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E, as outlined in recent Street research. Analyst Commentary Recent Street research around Lisata Therapeutics highlights a wide range of views, with some investors focusing on execution risks and others pointing to upside potential if key assumptions play out as expected.
ナラティブの更新 • Mar 05

LSTA: Brookline Downgrade And Acquisition Offer Will Reset Expectations For Upside

Analysts have adjusted their price target on Lisata Therapeutics to $15.00. The change reflects updated assumptions around revenue growth, profit margins and future P/E expectations following recent research, including a downgrade at Brookline.
ナラティブの更新 • Feb 18

LSTA: Pending Kuva Acquisition And Contingent Rights Will Support Future Upside

Analysts have reduced their price target on Lisata Therapeutics from $13.00 to approximately $11.33. They cited updated assumptions around fair value, discount rate, long-term revenue growth, profit margins, and future P/E multiples following recent changes in research coverage.
ナラティブの更新 • Feb 04

LSTA: Acquisition Offer And Downgrade Reset Expectations Before Potential Upside

Analysts have trimmed their price target on Lisata Therapeutics from US$15 to US$15.00, reflecting updated assumptions around revenue growth, profit margins, discount rates, and a higher future P/E multiple following recent research, including a downgrade from Brookline. Analyst Commentary Despite the recent trim in the headline price target, bullish analysts still see room for upside if Lisata executes on its plans and delivers against current expectations.
ナラティブの更新 • Jan 21

LSTA: Refined Risk Assumptions Will Support Future Upside Despite Recent Downgrade

Analysts have slightly reduced their fair value estimate to US$13.00, citing modest adjustments to the discount rate, long term profit margin expectations, and a lower implied future P/E as they reassess Lisata Therapeutics following a recent downgrade in Street research. Analyst Commentary Bullish Takeaways Bullish analysts view the revised US$13.00 fair value as still reflecting upside potential, provided that execution on key clinical and operational milestones tracks internal expectations.
ナラティブの更新 • Jan 07

LSTA: Improved Profitability Assumptions Will Support Strong Future Upside Potential

Analysts have modestly lifted their price target for Lisata Therapeutics, citing slightly improved profit margin assumptions at 16.24% and a lower future P/E estimate of 103.37x as key drivers of their updated valuation. Valuation Changes Fair Value: Remains unchanged at 13.0, suggesting the overall valuation anchor has been kept steady.
ナラティブの更新 • Dec 24

LSTA: Upcoming Pancreatic Cancer Data And Catalent Deal Will Drive Shares

Analysts have reduced their price target on Lisata Therapeutics from 32.00 dollars to 15.00 dollars, citing higher discount rates despite stronger projected revenue growth, improved profit margins, and a materially lower future price-to-earnings multiple. What's in the News Lisata Therapeutics and Catalent signed a global product license agreement granting Catalent non exclusive worldwide rights to incorporate certepetide into antibody drug conjugates using its SMARTag technology platform, including the ability to partner with third parties (Key Developments) Under the Catalent collaboration, Lisata is eligible for more than 10 million dollars in tiered study initiation milestone payments plus revenue sharing on future product sales and partnerships (Key Developments) Certepetide, Lisata's proprietary iRGD cyclic peptide, has shown favorable safety, tolerability, and clinical activity in trials aimed at improving the effectiveness of standard of care chemotherapy for pancreatic cancer and other solid tumors (Key Developments) Certepetide has received multiple regulatory designations, including Fast Track and Orphan Drug Designation for pancreatic cancer in the U.S. and E.U., Orphan Drug Designation for glioma and osteosarcoma in the U.S., and Rare Pediatric Disease Designation for osteosarcoma in the U.S. (Key Developments) Preliminary data from the PDAC cohort of the Phase 1/2a CENDIFOX trial of certepetide plus FOLFIRINOX based therapies will be presented at the AACR Special Conference in Cancer Research on Advances in Pancreatic Cancer Research on September 29, 2025, in Boston, Massachusetts (Key Developments) Valuation Changes Fair Value Estimate: Reduced significantly from 32 dollars to 15 dollars per share, reflecting a more conservative assessment despite stronger fundamentals.
ナラティブの更新 • Dec 09

LSTA: Upcoming Cancer Trial Milestones Will Drive Strong Upside Potential

Analysts have nudged their price target on Lisata Therapeutics slightly higher to 13.00 dollars from 13.00 dollars, reflecting modest adjustments to the discount rate and long-term valuation assumptions, despite largely unchanged growth and margin expectations. What's in the News Lisata Therapeutics and Catalent entered a global product license agreement granting Catalent worldwide, non exclusive rights to use certepetide in antibody drug conjugates developed on its SMARTag platform, with Lisata eligible for over 10 million dollars in tiered milestone payments plus revenue sharing on future sales and partnerships (Key Developments) Certepetide, Lisata's proprietary internalizing RGD cyclic peptide, will be evaluated by Catalent as a payload across multiple ADCs targeting difficult to treat diseases.
ナラティブの更新 • Nov 25

LSTA: Global Licensing Milestones And Trial Results Will Drive Future Upside

Analysts have raised their price target for Lisata Therapeutics slightly, increasing it from $13.00 to $13.00 per share. This reflects updated projections for profitability and valuation metrics.
ナラティブの更新 • Nov 09

LSTA: Milestone Payments And Clinical Progress Will Drive Future Upside

Analysts have revised their price target for Lisata Therapeutics from $20.67 to $13.00, citing updated financial assumptions and outlook. What's in the News Lisata Therapeutics and Catalent have entered a global product license agreement, granting Catalent non-exclusive rights to develop and commercialize bioconjugate products containing certepetide using the SMARTag technology platform.
分析記事 • Aug 13

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Apr 26

We Think Lisata Therapeutics (NASDAQ:LSTA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
User avatar
新しいナラティブ • Apr 14

Certepetide Advancements And Regulatory Approvals Will Set New Care Standards

Advancements in certepetide and regulatory achievements could expedite market entry, fostering revenue growth and enhancing treatment standards.
分析記事 • Dec 24

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Jul 15

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Mar 22

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Sep 15

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 14

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Caladrius Biosciences (NASDAQ:CLBS) announced that its stockholders approved all of the merger-related proposals by Caladrius and Cend Therapeutics, and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock to Cend’s stockholders. Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding. The reverse stock split will become effective today, Sept. 14, 2022, at 5:00pm EST. The consolidated common shares for the combined company, which will be renamed Lisata Therapeutics, are expected to commence trading on Nasdaq under the symbol “LSTA” on Sept. 15, 2022, at 9:30am EST. CLBS +39.28% premarket to $0.71.
Seeking Alpha • Aug 04

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Caladrius Biosciences press release (NASDAQ:CLBS): Q2 GAAP EPS of -$0.11 beats by $0.01. As of June 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $73 million. Merger with Cend Therapeutics remains on track to close in Q3.
分析記事 • May 02

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jan 05

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • May 09

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Nov 30

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

決済の安定と成長

配当データの取得

安定した配当: LSTAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: LSTAの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Lisata Therapeutics 配当利回り対市場
LSTA 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (LSTA)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Biotechs)2.4%
アナリスト予想 (LSTA) (最長3年)n/a

注目すべき配当: LSTAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: LSTAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: LSTAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: LSTAが配当金を報告していないため、配当金の持続可能性を計算できません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/25 03:17
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Lisata Therapeutics, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11

アナリスト機関
Jan WaldBenchmark Company
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets